Nkarta has been granted a patent for genetically engineered NK cells expressing a CAR targeting CD70 for renal cell carcinoma immunotherapy. The cells are edited to reduce self-targeting markers and express membrane-bound IL-15 for enhanced efficacy. GlobalData’s report on Nkarta gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Nkarta, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Nkarta's grant share as of May 2024 was 2%. Grant share is based on the ratio of number of grants to total number of patents.
Genetically engineered nk cells for cd70-targeted immunotherapy
A recently granted patent (Publication Number: US12012458B2) discloses a population of genetically engineered natural killer (NK) cells that have been expanded in culture. These NK cells are modified to express a chimeric antigen receptor (CAR) targeting CD70, a protein associated with tumors. The engineered NK cells also express membrane-bound IL-15 and have reduced levels of CD70 protein due to genetic editing. The CAR includes specific amino acid sequences for the heavy and light chain variable regions, enhancing the NK cells' cytotoxicity against target cells.
Furthermore, the patent describes genetically engineered immune cells with similar modifications, including reduced expression of the cytokine-inducible SH2-containing (CIS) protein and other immune-related proteins. These engineered immune cells exhibit enhanced expansion capability, cytotoxicity, and persistence compared to non-edited cells. The patent also covers anti-CD70 CARs with specific binding domains and cytotoxic signaling complexes, providing a detailed framework for developing novel immunotherapies targeting CD70-positive tumors. Overall, the patent highlights the potential of genetically engineered immune cells in cancer treatment and underscores the importance of precise genetic editing for enhancing therapeutic outcomes.
To know more about GlobalData’s detailed insights on Nkarta, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
